There is currently no cure for rheumatoid arthritis, but remarkable progress has been made over the last two decades in therapeutic regimens, with the possibility of long-lasting remission and in particular, prevention of sequelae joint deformities, ankylosis, reduced mobility and functional capacity. Various drugs are used in the pharmacological treatment: nonsteroidal anti-inflammatory drugs, corticoids, disease-modifying anti-rheumatic drugs, biological agents acting on the immune system, reducing its erratic activity, with maximum efficacy combined with disease-modifying anti-rheumatic drugs.
Lancet ; : Shah A, St. Clair EW. Rheumatoid Arthritis. Harrison's Principles of Internal Medicine.
Таким образом можно завязать контакты между двумя видами, а потом заключить договор, скрепляющий взаимное согласие. - Иисусе. - воскликнул Ричард, выслушав в переводе речь Арчи. - А я-то считал идеалисткой Николь. Арчи не понял восклицания Ричарда.
Ann Rheum Dis ; 66 10 : Smoking, use of moist snuff, and risk of chronic inflam-matory diseases. Ann Rheum Dis ; 69 6 : Biomed Res Int ; Lung de ce condroitina glucozamină and drug-induced lung disease in patients with rheumatoid arthritis. Expert Rev Clin Immunol ; 9 7 : Nat Rev Rheumatol ; 6 12 : Updated consensus statement on biological agents for the treatment of rheumatic diseases.
Ann Rheum Dis ; 66 Suppl 3: iii Ann Rheum Dis ; 70 8 : Impact of biologic therapy on functional status in patients with rheumatoid arthritis - a meta-analysis. Rheumatology Oxford ; 52 12 : Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis ; 72 6 : Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
Arthritis Care Res Hoboken ; 63 5 : Curr Rheumatol Rep ; 20 12 : Report No. A randomized, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis SUMMACTA study.
Ann Rheum Dis ; 73 1 : Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis ; 68 7 : Tofacitinib CP, in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.
NOVEL APPROACHES IN THE PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS
Arthritis Rheum ; 65 3 : Cavalli G, Dinarello CA. Anakinra therapy for non-cancer inflammatory diseases. Front Pharmacol ; 9: Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomized, multicenter, double-blind, placebo-controlled GO-FURTHER trial.
Ann Rheum Dis ; 72 3 : Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis juvenile rheumatoid arthritis review an inadequate response to tumor necrosis factor inhibitor therapy.
J Rheumatol ; 39 8 juvenile rheumatoid arthritis review The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis.
Ann Rheum Dis ; 72 12 : New autoantibodies as biomarkers for early and seronega-tive rheumatoid arthritis [abstract OP]. Ann Rheum Dis ; 72 suppl 3 : The influence of rheumatoid arthritis disease character-istics on heart failure. J Rheumatol ; 38 8 : Placebo-controlled trial of tofacitinib monotherapy in rheuma-toid arthritis.
Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed and endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice.
N Engl J Med ; 6 : Fleischmann R. Novel small-molecular therapeutics for rheumatoid arthritis. Curr Opin Rheumatol b; 24 3 : Consensus statement on blocking the effects of inter-leukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other in-flammatory conditions.
Ann Rheum Dis ; 72 4 : An oral spleen tyrosine kinase Syk inhibitor for rheumatoid arthritis. N Engl J Med ; 14 :
- RJR Vol. XXVI, No. 2, Year – Romanian Journal of Rheumatology
- RJR Vol. XXIV, No. 4, Year – Romanian Journal of Rheumatology
- Articulațiile doareau toate crizele
- Colagen pentru par